Dr. Bilezikian is Chief of the Division of Endocrinology and Director of the Metabolic Bone Diseases Program at Columbia University Medical Center. He belongs to the American Society for Bone and Mineral Research (President 1995-1996), and the International Society of Clinical Densitometry (President, 1999-2001). He serves on the Board of Governors of the International Osteoporosis Foundation (1998-present) and on its Committee of Scientific Advisors (2001-present) and is Chair of the Endocrine Fellows Foundation. He served as Editor-in-Chief of the Journal of Clinical Endocrinology and Metabolism (2000-2004) and as Senior Associate Editor of the Journal of Bone and Mineral Research (2008-2012). He is Executive Advisory Editor of Bone Research (2013-present). He served as co-chair of the last three NIH Workshops on Primary Hyperparathyroidism (2002, 2008, 2013). Dr. Bilezikian is the recipient of the Distinguished Physician Award of the Endocrine Society, the Frederic C. Bartter Award of the American Society for Bone and Mineral Research (ASBMR) for Excellence in Clinical Research and the First Annual Global Leadership Award of the International Society of Clinical Densitometry. In 2009, he received the Gideon A. Rodan Excellence in Mentorship Award from the ASBMR. He received the Laureate Distinguished Educator Award of The Endocrine Society in 2014. In 2014, he was made honorary member of the Brazilian Society of Endocrinology and Metabolism. His publications number over 700. Dr. Martin has served on 12 state and national committees and boards, been an international lecturer for nearly 20 years, and his work has been extensively published in a total of 420 original papers, 178 reviews, chapters and editorials, and seven books. He was appointed as Officer of the Order of Australia, elected to fellowships of the Australian Academy and the Royal Society and received 12 prestigious career awards, including the Eric Susman Prize from the Royal Australasian College of Physician. He has had 12 patents granted and held eight international visiting appointments in the United Kingdom, United States, and Switzerland. An outstanding contribution to science includes the cloning of parathyroid hormone related protein. Thomas Clemens works at the Johns Hopkins University in the Department of Orthopaedic Surgery, Baltimore, MD, USA Dr. Rosen is Professor and Senior Scientists at The Jackson Laboratory, Bar Harbor, Maine, where his group studies the role of insulin-like growth factors on bone and the genetics of osteoporosis in inbred strains of mice. In 2007 he joined the Maine Medical Center Research Institute in Scarborough, Maine. He is also the former Director of the Maine Center for Osteoporosis Research and Education, St. Joseph Hospital, Bangor.Dr. Rosen is a Past President of the American Society of Bone and Mineral Research (ASBMR). He served five years as the First Editor in Chief of the Journal of Clinical Densitometry, the official journal for the International Society of Clinical Densitometry, and currently serves as Associate Editor of the Journal of Bone and Mineral Research. His publications exceed 270 manuscripts published in a wide spectrum of clinical and basic science journals.

Review of the previous edition:"Students, teachers, and practitioners will benefit from reading it, and investigators will use it as a reference work; it will certainly be consulted frequently." --The New England Journal of Medicine

• Volume 1Part I: Basic principlesSection A Cell biology1. Molecular and cellular regulation of intramembranous and endochondral bone formation during embryogenesis2. Skeletal stem cells: tissue-specific stem/progenitor cells of cartilage, bone, stroma, and marrow adipocytes3. Bone marrow and the hematopoietic stem cell niche4. The osteoblast lineage: its actions and communication mechanisms5. Osteoclasts6. The osteocyte7. Transcriptional control of osteoblast differentiation and function8. Wnt signaling and bone cell activity9. Vascular and nerve interactions10. Coupling of bone formation and resorption11. Modeling and remodeling: the cellular machinery responsible for bone’s material and structural strength during growth, aging, and drug therapy12. Aging and boneSection B Biochemistry13. Type I collagen structure, synthesis, and regulation14. Collagen cross-linking and bone pathobiology15. Secreted noncollagenous proteins of bone16. Bone proteinases17. Integrins and other cell surface attachment molecules of bone cells18. Intercellular junctions and cellecell communication in the skeletal systemSection C Bone remodeling and mineral homeostasis19. Histomorphometric analysis of bone remodeling20. Phosphorus homeostasis and related disorders21. Magnesium homeostasis22. Metal ion toxicity in the skeleton: lead and aluminum23. Biology of the extracellular calcium-sensing receptorSection D Endocrine and paracrine regulation of bone24. Parathyroid hormone molecular biology25. Paracrine parathyroid hormonee related protein in bone: physiology and pharmacology26. Cardiovascular actions of parathyroid hormone/parathyroid hormoneerelated protein signaling27. Parathyroid hormone and parathyroid hormoneerelated protein actions on bone and kidney28. Receptors for parathyroid hormone and parathyroid hormoneerelated protein29. Structure and function of the vitamin D-binding proteins30. Vitamin D gene regulation31. Nonskeletal effects of vitamin D: current status and potential paths forward32. Cellular actions of parathyroid hormone on bone33. Calcitonin peptides34. Regulation of bone remodeling by central and peripheral nervous signalsSection E Other systemic hormones that influence bone metabolism35. Estrogens and progestins36. Physiological actions of parathyroid hormone-related protein in epidermal, mammary, reproductive, and pancreatic tissues37. The pharmacology of selective estrogen receptor modulators: past and present38. Thyroid hormone and bone39. Basic and clinical aspects of glucocorticoid action in bone40. Diabetes and bone41. Androgen receptor expression and steroid action in boneSection F Local regulators42. Growth hormone, insulin-like growth factors, and IGF binding proteinsVolume 243. The periodontium44. Notch and its ligands45. Fibroblast growth factor (FGF) and FGF receptor families in bone46. Vascular endothelial growth factor and boneevascular interactions47. Transforming growth factor-b and skeletal homeostasis48. Bone morphogenetic proteins49. Extraskeletal effects of RANK ligand50. Local regulators of bone51. Prostaglandins and bone metabolismPart II: Molecular mechanisms of metabolic bone disease52. The molecular actions of parathyroid hormone/parathyroid hormoneerelated protein receptor type 1 and their implications53. Multiple endocrine neoplasia type 154. Parathyroid hormone-related peptide and other mediators of skeletal manifestations of malignancy55. Localized osteolysis56. Genetic regulation of parathyroid gland development57. Genetic disorders caused by mutations in the parathyroid hormone/parathyroid hormonee related peptide receptor, its ligands, and downstream effector molecules58. Molecular basis of parathyroid hormone overexpression59. Diseases resulting from defects in the G protein Gsa60. Renal osteodystrophy and chronic kidney diseaseemineral bone disorder61. Osteogenesis imperfecta62. Hereditary deficiencies in vitamin D action63. Fibroblast growth factor 2364. Tumor-induced osteomalacia65. Osteopetrosis66. Hypophosphatasia: nature’s window on alkaline phosphatase function in humans67. Paget’s disease of bone68. Genetic determinants of bone mass and osteoporotic fracturePart III: Pharmacological mechanisms of therapeutics69. Pharmacologic mechanisms of therapeutics: parathyroid hormone70. Calcium71. Drugs acting on the calcium receptor: calcimimetics and calcilytics72. Clinical and translational pharmacology of bisphosphonates73. Pharmacological mechanisms of therapeutics: receptor activator of nuclear factorekappa B ligand inhibition74. Pharmacologic basis of sclerostin inhibition75. Vitamin D and its analogs76. Mechanisms of exercise effects on bone quantity and qualityPart IV: Methods in bone research77. Application of genetically modified animals in bone research78. Bone turnover markers79. Microimaging80. Macroimaging81. Methods in lineage tracing82. Bone histomorphometry in rodents83. Bone strength testing in rodents84. Regulation of energy metabolism by bone-derived hormones

Dr. Bilezikian is Chief of the Division of Endocrinology and Director of the Metabolic Bone Diseases Program at Columbia University Medical Center. He belongs to the American Society for Bone and Mineral Research (President 1995-1996), and the International Society of Clinical Densitometry (President, 1999-2001). He serves on the Board of Governors of the International Osteoporosis Foundation (1998-present) and on its Committee of Scientific Advisors (2001-present) and is Chair of the Endocrine Fellows Foundation. He served as Editor-in-Chief of the Journal of Clinical Endocrinology and Metabolism (2000-2004) and as Senior Associate Editor of the Journal of Bone and Mineral Research (2008-2012). He is Executive Advisory Editor of Bone Research (2013-present). He served as co-chair of the last three NIH Workshops on Primary Hyperparathyroidism (2002, 2008, 2013). Dr. Bilezikian is the recipient of the Distinguished Physician Award of the Endocrine Society, the Frederic C. Bartter Award of the American Society for Bone and Mineral Research (ASBMR) for Excellence in Clinical Research and the First Annual Global Leadership Award of the International Society of Clinical Densitometry. In 2009, he received the Gideon A. Rodan Excellence in Mentorship Award from the ASBMR. He received the Laureate Distinguished Educator Award of The Endocrine Society in 2014. In 2014, he was made honorary member of the Brazilian Society of Endocrinology and Metabolism. His publications number over 700. Dr. Martin has served on 12 state and national committees and boards, been an international lecturer for nearly 20 years, and his work has been extensively published in a total of 420 original papers, 178 reviews, chapters and editorials, and seven books. He was appointed as Officer of the Order of Australia, elected to fellowships of the Australian Academy and the Royal Society and received 12 prestigious career awards, including the Eric Susman Prize from the Royal Australasian College of Physician. He has had 12 patents granted and held eight international visiting appointments in the United Kingdom, United States, and Switzerland. An outstanding contribution to science includes the cloning of parathyroid hormone related protein. Thomas Clemens works at the Johns Hopkins University in the Department of Orthopaedic Surgery, Baltimore, MD, USA Dr. Rosen is Professor and Senior Scientists at The Jackson Laboratory, Bar Harbor, Maine, where his group studies the role of insulin-like growth factors on bone and the genetics of osteoporosis in inbred strains of mice. In 2007 he joined the Maine Medical Center Research Institute in Scarborough, Maine. He is also the former Director of the Maine Center for Osteoporosis Research and Education, St. Joseph Hospital, Bangor.Dr. Rosen is a Past President of the American Society of Bone and Mineral Research (ASBMR). He served five years as the First Editor in Chief of the Journal of Clinical Densitometry, the official journal for the International Society of Clinical Densitometry, and currently serves as Associate Editor of the Journal of Bone and Mineral Research. His publications exceed 270 manuscripts published in a wide spectrum of clinical and basic science journals.

Review of the previous edition:"Students, teachers, and practitioners will benefit from reading it, and investigators will use it as a reference work; it will certainly be consulted frequently." --The New England Journal of Medicine

• Volume 1Part I: Basic principlesSection A Cell biology1. Molecular and cellular regulation of intramembranous and endochondral bone formation during embryogenesis2. Skeletal stem cells: tissue-specific stem/progenitor cells of cartilage, bone, stroma, and marrow adipocytes3. Bone marrow and the hematopoietic stem cell niche4. The osteoblast lineage: its actions and communication mechanisms5. Osteoclasts6. The osteocyte7. Transcriptional control of osteoblast differentiation and function8. Wnt signaling and bone cell activity9. Vascular and nerve interactions10. Coupling of bone formation and resorption11. Modeling and remodeling: the cellular machinery responsible for bone’s material and structural strength during growth, aging, and drug therapy12. Aging and boneSection B Biochemistry13. Type I collagen structure, synthesis, and regulation14. Collagen cross-linking and bone pathobiology15. Secreted noncollagenous proteins of bone16. Bone proteinases17. Integrins and other cell surface attachment molecules of bone cells18. Intercellular junctions and cellecell communication in the skeletal systemSection C Bone remodeling and mineral homeostasis19. Histomorphometric analysis of bone remodeling20. Phosphorus homeostasis and related disorders21. Magnesium homeostasis22. Metal ion toxicity in the skeleton: lead and aluminum23. Biology of the extracellular calcium-sensing receptorSection D Endocrine and paracrine regulation of bone24. Parathyroid hormone molecular biology25. Paracrine parathyroid hormonee related protein in bone: physiology and pharmacology26. Cardiovascular actions of parathyroid hormone/parathyroid hormoneerelated protein signaling27. Parathyroid hormone and parathyroid hormoneerelated protein actions on bone and kidney28. Receptors for parathyroid hormone and parathyroid hormoneerelated protein29. Structure and function of the vitamin D-binding proteins30. Vitamin D gene regulation31. Nonskeletal effects of vitamin D: current status and potential paths forward32. Cellular actions of parathyroid hormone on bone33. Calcitonin peptides34. Regulation of bone remodeling by central and peripheral nervous signalsSection E Other systemic hormones that influence bone metabolism35. Estrogens and progestins36. Physiological actions of parathyroid hormone-related protein in epidermal, mammary, reproductive, and pancreatic tissues37. The pharmacology of selective estrogen receptor modulators: past and present38. Thyroid hormone and bone39. Basic and clinical aspects of glucocorticoid action in bone40. Diabetes and bone41. Androgen receptor expression and steroid action in boneSection F Local regulators42. Growth hormone, insulin-like growth factors, and IGF binding proteinsVolume 243. The periodontium44. Notch and its ligands45. Fibroblast growth factor (FGF) and FGF receptor families in bone46. Vascular endothelial growth factor and boneevascular interactions47. Transforming growth factor-b and skeletal homeostasis48. Bone morphogenetic proteins49. Extraskeletal effects of RANK ligand50. Local regulators of bone51. Prostaglandins and bone metabolismPart II: Molecular mechanisms of metabolic bone disease52. The molecular actions of parathyroid hormone/parathyroid hormoneerelated protein receptor type 1 and their implications53. Multiple endocrine neoplasia type 154. Parathyroid hormone-related peptide and other mediators of skeletal manifestations of malignancy55. Localized osteolysis56. Genetic regulation of parathyroid gland development57. Genetic disorders caused by mutations in the parathyroid hormone/parathyroid hormonee related peptide receptor, its ligands, and downstream effector molecules58. Molecular basis of parathyroid hormone overexpression59. Diseases resulting from defects in the G protein Gsa60. Renal osteodystrophy and chronic kidney diseaseemineral bone disorder61. Osteogenesis imperfecta62. Hereditary deficiencies in vitamin D action63. Fibroblast growth factor 2364. Tumor-induced osteomalacia65. Osteopetrosis66. Hypophosphatasia: nature’s window on alkaline phosphatase function in humans67. Paget’s disease of bone68. Genetic determinants of bone mass and osteoporotic fracturePart III: Pharmacological mechanisms of therapeutics69. Pharmacologic mechanisms of therapeutics: parathyroid hormone70. Calcium71. Drugs acting on the calcium receptor: calcimimetics and calcilytics72. Clinical and translational pharmacology of bisphosphonates73. Pharmacological mechanisms of therapeutics: receptor activator of nuclear factorekappa B ligand inhibition74. Pharmacologic basis of sclerostin inhibition75. Vitamin D and its analogs76. Mechanisms of exercise effects on bone quantity and qualityPart IV: Methods in bone research77. Application of genetically modified animals in bone research78. Bone turnover markers79. Microimaging80. Macroimaging81. Methods in lineage tracing82. Bone histomorphometry in rodents83. Bone strength testing in rodents84. Regulation of energy metabolism by bone-derived hormones

Dr. Bilezikian is Chief of the Division of Endocrinology and Director of the Metabolic Bone Diseases Program at Columbia University Medical Center. He belongs to the American Society for Bone and Mineral Research (President 1995-1996), and the International Society of Clinical Densitometry (President, 1999-2001). He serves on the Board of Governors of the International Osteoporosis Foundation (1998-present) and on its Committee of Scientific Advisors (2001-present) and is Chair of the Endocrine Fellows Foundation. He served as Editor-in-Chief of the Journal of Clinical Endocrinology and Metabolism (2000-2004) and as Senior Associate Editor of the Journal of Bone and Mineral Research (2008-2012). He is Executive Advisory Editor of Bone Research (2013-present). He served as co-chair of the last three NIH Workshops on Primary Hyperparathyroidism (2002, 2008, 2013). Dr. Bilezikian is the recipient of the Distinguished Physician Award of the Endocrine Society, the Frederic C. Bartter Award of the American Society for Bone and Mineral Research (ASBMR) for Excellence in Clinical Research and the First Annual Global Leadership Award of the International Society of Clinical Densitometry. In 2009, he received the Gideon A. Rodan Excellence in Mentorship Award from the ASBMR. He received the Laureate Distinguished Educator Award of The Endocrine Society in 2014. In 2014, he was made honorary member of the Brazilian Society of Endocrinology and Metabolism. His publications number over 700. Dr. Martin has served on 12 state and national committees and boards, been an international lecturer for nearly 20 years, and his work has been extensively published in a total of 420 original papers, 178 reviews, chapters and editorials, and seven books. He was appointed as Officer of the Order of Australia, elected to fellowships of the Australian Academy and the Royal Society and received 12 prestigious career awards, including the Eric Susman Prize from the Royal Australasian College of Physician. He has had 12 patents granted and held eight international visiting appointments in the United Kingdom, United States, and Switzerland. An outstanding contribution to science includes the cloning of parathyroid hormone related protein. Thomas Clemens works at the Johns Hopkins University in the Department of Orthopaedic Surgery, Baltimore, MD, USA Dr. Rosen is Professor and Senior Scientists at The Jackson Laboratory, Bar Harbor, Maine, where his group studies the role of insulin-like growth factors on bone and the genetics of osteoporosis in inbred strains of mice. In 2007 he joined the Maine Medical Center Research Institute in Scarborough, Maine. He is also the former Director of the Maine Center for Osteoporosis Research and Education, St. Joseph Hospital, Bangor.Dr. Rosen is a Past President of the American Society of Bone and Mineral Research (ASBMR). He served five years as the First Editor in Chief of the Journal of Clinical Densitometry, the official journal for the International Society of Clinical Densitometry, and currently serves as Associate Editor of the Journal of Bone and Mineral Research. His publications exceed 270 manuscripts published in a wide spectrum of clinical and basic science journals.

Review of the previous edition:"Students, teachers, and practitioners will benefit from reading it, and investigators will use it as a reference work; it will certainly be consulted frequently." --The New England Journal of Medicine

• Volume 1Part I: Basic principlesSection A Cell biology1. Molecular and cellular regulation of intramembranous and endochondral bone formation during embryogenesis2. Skeletal stem cells: tissue-specific stem/progenitor cells of cartilage, bone, stroma, and marrow adipocytes3. Bone marrow and the hematopoietic stem cell niche4. The osteoblast lineage: its actions and communication mechanisms5. Osteoclasts6. The osteocyte7. Transcriptional control of osteoblast differentiation and function8. Wnt signaling and bone cell activity9. Vascular and nerve interactions10. Coupling of bone formation and resorption11. Modeling and remodeling: the cellular machinery responsible for bone’s material and structural strength during growth, aging, and drug therapy12. Aging and boneSection B Biochemistry13. Type I collagen structure, synthesis, and regulation14. Collagen cross-linking and bone pathobiology15. Secreted noncollagenous proteins of bone16. Bone proteinases17. Integrins and other cell surface attachment molecules of bone cells18. Intercellular junctions and cellecell communication in the skeletal systemSection C Bone remodeling and mineral homeostasis19. Histomorphometric analysis of bone remodeling20. Phosphorus homeostasis and related disorders21. Magnesium homeostasis22. Metal ion toxicity in the skeleton: lead and aluminum23. Biology of the extracellular calcium-sensing receptorSection D Endocrine and paracrine regulation of bone24. Parathyroid hormone molecular biology25. Paracrine parathyroid hormonee related protein in bone: physiology and pharmacology26. Cardiovascular actions of parathyroid hormone/parathyroid hormoneerelated protein signaling27. Parathyroid hormone and parathyroid hormoneerelated protein actions on bone and kidney28. Receptors for parathyroid hormone and parathyroid hormoneerelated protein29. Structure and function of the vitamin D-binding proteins30. Vitamin D gene regulation31. Nonskeletal effects of vitamin D: current status and potential paths forward32. Cellular actions of parathyroid hormone on bone33. Calcitonin peptides34. Regulation of bone remodeling by central and peripheral nervous signalsSection E Other systemic hormones that influence bone metabolism35. Estrogens and progestins36. Physiological actions of parathyroid hormone-related protein in epidermal, mammary, reproductive, and pancreatic tissues37. The pharmacology of selective estrogen receptor modulators: past and present38. Thyroid hormone and bone39. Basic and clinical aspects of glucocorticoid action in bone40. Diabetes and bone41. Androgen receptor expression and steroid action in boneSection F Local regulators42. Growth hormone, insulin-like growth factors, and IGF binding proteinsVolume 243. The periodontium44. Notch and its ligands45. Fibroblast growth factor (FGF) and FGF receptor families in bone46. Vascular endothelial growth factor and boneevascular interactions47. Transforming growth factor-b and skeletal homeostasis48. Bone morphogenetic proteins49. Extraskeletal effects of RANK ligand50. Local regulators of bone51. Prostaglandins and bone metabolismPart II: Molecular mechanisms of metabolic bone disease52. The molecular actions of parathyroid hormone/parathyroid hormoneerelated protein receptor type 1 and their implications53. Multiple endocrine neoplasia type 154. Parathyroid hormone-related peptide and other mediators of skeletal manifestations of malignancy55. Localized osteolysis56. Genetic regulation of parathyroid gland development57. Genetic disorders caused by mutations in the parathyroid hormone/parathyroid hormonee related peptide receptor, its ligands, and downstream effector molecules58. Molecular basis of parathyroid hormone overexpression59. Diseases resulting from defects in the G protein Gsa60. Renal osteodystrophy and chronic kidney diseaseemineral bone disorder61. Osteogenesis imperfecta62. Hereditary deficiencies in vitamin D action63. Fibroblast growth factor 2364. Tumor-induced osteomalacia65. Osteopetrosis66. Hypophosphatasia: nature’s window on alkaline phosphatase function in humans67. Paget’s disease of bone68. Genetic determinants of bone mass and osteoporotic fracturePart III: Pharmacological mechanisms of therapeutics69. Pharmacologic mechanisms of therapeutics: parathyroid hormone70. Calcium71. Drugs acting on the calcium receptor: calcimimetics and calcilytics72. Clinical and translational pharmacology of bisphosphonates73. Pharmacological mechanisms of therapeutics: receptor activator of nuclear factorekappa B ligand inhibition74. Pharmacologic basis of sclerostin inhibition75. Vitamin D and its analogs76. Mechanisms of exercise effects on bone quantity and qualityPart IV: Methods in bone research77. Application of genetically modified animals in bone research78. Bone turnover markers79. Microimaging80. Macroimaging81. Methods in lineage tracing82. Bone histomorphometry in rodents83. Bone strength testing in rodents84. Regulation of energy metabolism by bone-derived hormones